BC-DXI-843 - CAS:2421117-98-6

您当前的位置：

BC-DXI-843

目录号 : KM5142 CAS No. : 2421117-98-6 纯度 : 98%

Data Sheet 产品使用指南

BC-DXI-843 是一种有效的特异性 AIMP2-DX2 抑制剂，IC₅₀ 为 0.92 μM，比作用于 AIMP2 (IC50 >100 μM) 选择性高 100 倍以上。BC-DXI-843 有潜力用于 AIMP2-DX2 肺癌的研究。

规格	价格	是否有货
5mg		In-stock
10mg		In-stock
25mg		In-stock
50mg		In-stock
100mg	询价	In-stock
200mg	询价	In-stock

查看所有商品（1）

加入购物车大包装询价

Other Forms of Rapamycin:

Ginkgolide B In-stock
Isoginkgetin In-stock
Ginkgolic acid C17:1 In-stock
Ginkgolic Acid In-stock
Propargyl-PEG4-amine In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

BC-DXI-843 is a potent and specific AIMP2-DX2 inhibitor with an IC₅₀ of 0.92 μM, more than 100-fold selectivity over AIMP2 (IC₅₀ >100 μM) in a luciferase assay. BC-DXI-843 acts as a promising lead targeting AIMP2-DX2 in lung cancer.

体外研究

BC-DXI-843 (0.0316-31.6 μM; 72 hours) suppresses cancer cell proliferation in a DX2-dependent manner. The EC₅₀ in A549 cells is 1.20 μM, which is similar to the IC₅₀ for inhibition of DX2. However, no inhibition of WI-26 cells is observed, suggesting that BC-DXI-843 specifically reduces the viability of cancer cells.

Cell Proliferation Assay

Cell Line:	A549 cancer cells and WI-26 normal cells
Concentration:	0.0316, 0.1, 0.316, 1, 3.16, 10, 31.6 μM
Incubation Time:	72 hours
Result:	The EC₅₀ in A549 cells was 1.20 μM. No inhibition of WI-26 cells was observed.

体内研究

BC-DXI-843 (50 mg/kg; intraperitoneally administered; every other day for 15 days) demonstrates in vivo efficacy in a tumor xenograft mouse model (H460 cells).

Animal Model:	7-week-old female BALB/cSLC-nu/nu mice bearing H460 cells xenograft
Dosage:	50 mg/kg
Administration:	Intraperitoneally administered; every other day for 15 days
Result:	The embedded tumor volume gradually declined after BC-DXI-843administration, but no changes in body weight were observed. The weight of the excised tumors after sacrifice had decreased in mice.

分子式

C₂₈H₂₆N₄O₄S₂

分子量

546.66

CAS号

2421117-98-6

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据

In Vitro:

DMSO : 250 mg/mL (457.32 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.8293 mL	9.1465 mL	18.2929 mL
5 mM	0.3659 mL	1.8293 mL	3.6586 mL
10 mM	0.1829 mL	0.9146 mL	1.8293 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (3.80 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (3.80 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

纯度： 98%

Data Sheet

产品使用指南

暂无相关参考文献

摩尔计算器
稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量

浓度

体积

分子量*

重置计算

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2

浓度

体积

浓度

体积

重置计算

Other Forms of Rapamycin:

KKL 顾客使用本产品发表的 0 篇科研文献

The molarity calculator equation

The dilution calculator equation